NasdaqGS:JAZZPharmaceuticals
Jazz Pharmaceuticals (JAZZ) Reframed Zepzelca Growth, Is The Stock Still Below Fair Value?
Why Jazz Pharmaceuticals stock is back in focus after mixed cancer updates
Jazz Pharmaceuticals (JAZZ) is back on investors’ radar after the company reported a phase 3 setback for Zepzelca in second-line small cell lung cancer and, in parallel, highlighted growth potential in its first-line maintenance indication.
At the same time, Jazz Pharmaceuticals announced a new collaboration with AbCellera to discover T cell engaging multispecific antibodies for gastrointestinal cancers and other solid...